Mercurna BV is a biotech start-up, established in 2017 with the goal to develop life-changing medicines based on messenger RNA (mRNA). They exploit a technology platform that consists of the integrated development of 3 complementary modalities; (i) de-immunized mRNA, (ii) lipid nanoparticles (LNP) for delivery, and (iii) targeting moieties for specific cell targeting, together forming a nanoparticle to be used as nanomedicine. They are located at the Pivot Park in Oss, The Netherlands, a large biopharmaceutical campus with world-class R&D infrastructure that hosts around 60 start-ups,
scale-ups, SME’s.
Within NANEMIAR, Mercurna will be exploiting their platform to develop a novel targeted mRNA therapeutic for congenital anemia, with beta-thalassemia as proof of concept. Mercurna will be responsible for the development of the therapeutic mRNA and aims to establish novel targeted LNPs that allow for delivery to hematopoietic stem cells residing in the bone marrow.
Principal Investigator: Dr. Jenny van Asbeck-van der Wijst (SCOPUS Profile)